Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Jan Stefan van der Walt"'
Autor:
Andrzej M. Kierzek, Timothy P. Hickling, Isabel Figueroa, J. Cory Kalvass, Marjoleen Nijsen, Krithika Mohan, Geertruida M. Veldman, Akihiro Yamada, Hiroyuki Sayama, Sachiko Yokoo, Abhishek Gulati, Renu S. Dhanikula, Jochem Gokemeijer, Tarek A. Leil, Craig J. Thalhauser, Mario Giorgi, Maciej J. Swat, Vijayalakshmi Chelliah, Ben G. Small, Neil Benson, Michael Walker, Kapil Gadkar, Valerie Quarmby, Rong Deng, Andrea Ferrante, Gemma L. Dickinson, Jan‐Stefan Van Der Walt, Lian Zhou, Xiaoying Chen, Hannah M. Jones, Jatin Narula, Sophie Tourdot, Thierry Lavé, Benjamin Ribba, Piet H. van derGraaf
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 11, Pp 773-776 (2019)
Externí odkaz:
https://doaj.org/article/368f598c595b469b8b9deb6681ea6d5a
Autor:
Jan-Stefan van der Walt, Joji Mori, Takahiro Nakayama, Kenichi Inoue, Yoshinori Ito, George W. Sledge, Yasuo Miyoshi, Tsutomu Kawaguchi, Masato Takahashi, Yoshinori Tanizawa, Masakazu Toi, Antonio Llombart-Cussac, Norikazu Masuda, Hiroji Iwata, Hirofumi Mukai, Sachi Sakaguchi
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This was a Japanese subpopulation analysis of MONARCH 2, a double-blind, randomized, placebo-controlled, phase 3 study of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-neg
Autor:
Jan-Stefan van der Walt, Emmanuel Chigutsa, Siva Rama Prasad Kambhampati, P. Kellie Turner, Amanda K. Sykes, Maria M. Posada
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 9, Pp 523-533 (2020)
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 9, Pp 523-533 (2020)
Abemaciclib is an oral anticancer drug that inhibits cyclin dependent kinases 4 and 6 and is metabolized by cytochrome P450 3A in the intestines and liver to active metabolites. The objectives were (1) to develop a mechanistic model to characterize t
Autor:
Yoshinori Tanizawa, Matthew P. Goetz, Masato Takahashi, Jan-Stefan van der Walt, Masakazu Toi, Eriko Tokunaga, Joji Mori, Tsutomu Kawaguchi
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This was a Japanese subpopulation analysis of MONARCH 3, a randomized, double-blind, placebo-controlled phase 3 study of abemaciclib plus nonsteroidal aromatase inhibitors (NSAIs) for initial therapy for advanced breast cancer (ABC). Metho
Autor:
Andrea Ferrante, Lian Zhou, Marjoleen Nijsen, J. Cory Kalvass, Renu S Dhanikula, Gemma L. Dickinson, Piet H. van der Graaf, Isabel Figueroa, Kapil Gadkar, Andrzej M. Kierzek, Neil Benson, Akihiro Yamada, Michael Walker, Benjamin Ribba, Thierry Lavé, Sophie Tourdot, Jan-Stefan van der Walt, Abhishek Gulati, Hiroyuki Sayama, Jatin Narula, Valerie Quarmby, Vijayalakshmi Chelliah, Ben G Small, Xiaoying Chen, Rong Deng, Sachiko Yokoo, Maciej J. Swat, Craig J. Thalhauser, Krithika Mohan, Hannah M. Jones, Geertruida M. Veldman, Timothy P. Hickling, Jochem Gokemeijer, Mario Giorgi, Tarek A. Leil
Publikováno v:
CPT Pharmacometrics Syst Pharmacol
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 11, Pp 773-776 (2019)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 11, Pp 773-776 (2019)
CPT: Pharmacometrics & Systems Pharmacology
Immunogenicity is a major challenge in drug development and patient care. Currently, most efforts are dedicated to the elimination of the unwanted immune responses through T‐cell epitope prediction and protein engineering. However, because it is un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1101d65d4d512bb2b5d4501d81dc7645
https://eprints.whiterose.ac.uk/153749/1/Kierzek_et_al-2019-CPT__Pharmacometrics_&_Systems_Pharmacology.pdf
https://eprints.whiterose.ac.uk/153749/1/Kierzek_et_al-2019-CPT__Pharmacometrics_&_Systems_Pharmacology.pdf
Autor:
Jean B. Nachega, Karen I. Barnes, Tamara Kredo, Alwin D. R. Huitema, Elin M. Svensson, Jan Stefan van der Walt, Mats O. Karlsson, Karen Cohen, Paolo Denti
Publikováno v:
British Journal of Clinical Pharmacology. 74:465-476
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Integrating individual data from multiple sources in one simultaneous population analysis (sometimes called a mega-model) can address novel research questions and add power for covariate detection without
Autor:
Paolo Denti, Pete Smith, Jan-Stefan van der Walt, Helen McIlleron, Mats O. Karlsson, Yuan Ren, Chao Zhang
Publikováno v:
Therapeutic Drug Monitoring. 34:481-484
Interpretation of antiretroviral drug concentration measurements could be aided by information about adherence to recent doses. We developed a population pharmacokinetic model of lamivudine in young children to propose reference lamivudine concentrat
Autor:
Mats O. Karlsson, Yuan Ren, Paolo Denti, Helen McIlleron, Jan-Stefan van der Walt, Chao Zhang, Ulrika S. H. Simonsson
Publikováno v:
Antiviral Therapy. 17:25-33
Background The preferred antiretroviral regimen for young children previously exposed to non-nucleoside reverse transcriptase inhibitors is lopinavir/ ritonavir plus two nucleoside reverse transcriptase inhibitors. Rifampicin-based antitubercular tre
Autor:
Jan-Stefan van der Walt, P. Bernard Fourie, Giorgio Roscigno, Helen McIlleron, D. A. Mitchison, Simbarashe P. Zvada, Pete Smith, Ulrika S. H. Simonsson
Publikováno v:
Antimicrobial Agents and Chemotherapy. 54:3390-3394
Rifapentine and its primary metabolite, 25-desacetyl rifapentine, are active against mycobacterium tuberculosis. The objectives of this study were to describe the population pharmacokinetics of rifapentine and 25-desacetyl rifapentine in fasting and
Autor:
Joyce Mordenti, Yoshiaki Ohtsu, Walter Krauwinkel, Jacqueline A. Gibbons, Vanessa Beddo, Taoufik Ouatas, Michiel de Vries, Jan-Stefan van der Walt
Publikováno v:
Clinical Pharmacokinetics
Background and Objectives Oral enzalutamide (160 mg once daily) is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This article describes the pharmacokinetics of enzalutamide and its active metabolite N-desmethy